{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:55:31Z","timestamp":1789152931198,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NAC"},{"name":"NAC"},{"name":"AUC"},{"name":"NAC"},{"name":"AMACMA society"},{"name":"Cabesan fruit enterprise"},{"name":"Carraclas Theater Company"},{"name":"Spanish Ministry of Science, Innovation and Universities"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejca.2020.08.020","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T06:21:59Z","timestamp":1601360519000},"page":"119-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer"],"prefix":"10.1016","volume":"139","author":[{"given":"Carmen","family":"Salvador-Coloma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Santaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sanmart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Herv\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8808-3423","authenticated-orcid":false,"given":"Lourdes","family":"Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Quintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-3572","authenticated-orcid":false,"given":"Francisco","family":"Ripoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Panadero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6816-2095","authenticated-orcid":false,"given":"Jaime","family":"Font de Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.08.020_bib1","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2020.08.020_bib2","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.08.020_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12885-016-2198-0","article-title":"Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients","volume":"16","author":"Ring","year":"2016","journal-title":"BMC Canc"},{"key":"10.1016\/j.ejca.2020.08.020_bib4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets","volume":"4","author":"Balko","year":"2014","journal-title":"Canc Discov"},{"issue":"Suppl 6","key":"10.1016\/j.ejca.2020.08.020_bib5","doi-asserted-by":"crossref","first-page":"vi35","DOI":"10.1093\/annonc\/mds193","article-title":"Neoadjuvant treatments for triple-negative breast cancer (TNBC)","volume":"23","author":"von Minckwitz","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.08.020_bib6","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.08.020_bib7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2020.08.020_bib8","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2020.08.020_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.08.020_bib10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.08.020_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2020.08.020_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ctrv.2016.09.019","article-title":"Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer","volume":"50","author":"Criscitiello","year":"2016","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.ejca.2020.08.020_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2020.08.020_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","article-title":"Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment","volume":"128","author":"Parker","year":"2015","journal-title":"Adv Canc Res"},{"key":"10.1016\/j.ejca.2020.08.020_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \"N1\" versus \"N2\" TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Canc Cell"},{"key":"10.1016\/j.ejca.2020.08.020_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ccr.2012.01.008","article-title":"Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells","volume":"21","author":"Engelhardt","year":"2012","journal-title":"Canc Cell"},{"key":"10.1016\/j.ejca.2020.08.020_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2020.08.020_bib18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/jclinpath-2015-202944","article-title":"Role of inflammatory infiltrates in triple negative breast cancer","volume":"68","author":"Matsumoto","year":"2015","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ejca.2020.08.020_bib19","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2020.08.020_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/nyas.12469","article-title":"Myeloid-derived suppressor cell heterogeneity in human cancers","volume":"1319","author":"Solito","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejca.2020.08.020_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00262-015-1782-5","article-title":"Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study","volume":"65","author":"Mandruzzato","year":"2016","journal-title":"Cancer Immunol, Immunother: CII"},{"key":"10.1016\/j.ejca.2020.08.020_bib22","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1002\/ijc.28622","article-title":"Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways","volume":"134","author":"Raber","year":"2014","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2020.08.020_bib23","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.4049\/jimmunol.1401282","article-title":"IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells","volume":"193","author":"Lim","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2020.08.020_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-015-0755-y","article-title":"Kinetics of human myeloid-derived suppressor cells after blood draw","volume":"14","author":"Grutzner","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2020.08.020_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/JLB.5AB0217-070R","article-title":"TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells","volume":"103","author":"Dang","year":"2018","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ejca.2020.08.020_bib26","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2020.08.020_bib27","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.18632\/oncotarget.6467","article-title":"Understanding the role of the kynurenine pathway in human breast cancer immunobiology","volume":"7","author":"Heng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2020.08.020_bib28","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1016\/S0021-9258(17)35696-X","article-title":"Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase","volume":"261","author":"Takikawa","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2020.08.020_bib29","first-page":"124","article-title":"Strong correlation of indoleamine 2,3-dioxygenase 1 expression with basal-like phenotype and increased lymphocytic infiltration in triple-negative breast cancer","volume":"8","author":"Kim","year":"2017","journal-title":"J Canc"},{"key":"10.1016\/j.ejca.2020.08.020_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/2326-6066.CIR-16-0182","article-title":"Promoter methylation modulates indoleamine 2,3-dioxygenase 1 induction by activated T cells in human breast cancers","volume":"5","author":"Noonepalle","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2020.08.020_bib31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2020.08.020_bib32","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1440-1827.2003.01547.x","article-title":"Cytometrical image analysis for immunohistochemical hormone receptor status in breast carcinomas","volume":"53","author":"Hatanaka","year":"2003","journal-title":"Pathol Int"},{"key":"10.1016\/j.ejca.2020.08.020_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.08.020_bib34","doi-asserted-by":"crossref","first-page":"17774","DOI":"10.1038\/s41598-017-17921-x","article-title":"Plasma sample based analysis of gastric cancer progression using targeted metabolomics","volume":"7","author":"Lario","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2020.08.020_bib35","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1093\/bioinformatics\/btw334","article-title":"Integrated gene set analysis for microRNA studies","volume":"32","author":"Garcia-Garcia","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejca.2020.08.020_bib36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2020.08.020_bib37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/02664769723918","article-title":"Interpretation of Kappa and B statistics measures of agreement","volume":"24","author":"Munoz","year":"1997","journal-title":"J Appl Stat"},{"key":"10.1016\/j.ejca.2020.08.020_bib38","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1073\/pnas.83.17.6622","article-title":"Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients","volume":"83","author":"Yasui","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2020.08.020_bib39","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ejca.2013.01.017","article-title":"Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells","volume":"49","author":"O'Brien","year":"2013","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.08.020_bib40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12967-018-1514-7","article-title":"Immunotherapeutic interventions of triple negative breast cancer","volume":"16","author":"Li","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2020.08.020_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-018-1163-y","article-title":"Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial","volume":"16","author":"Stevic","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2020.08.020_bib42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1541-7786.MCR-18-0362","article-title":"A role for tryptophan-2,3-dioxygenase in CD8 T-cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma","volume":"17","author":"Greene","year":"2019","journal-title":"Mol Canc Res"},{"key":"10.1016\/j.ejca.2020.08.020_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3389\/fimmu.2014.00497","article-title":"AhR-Mediated, non-genomic modulation of Ido1 function","volume":"5","author":"Pallotta","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2020.08.020_bib44","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I study of the indoleamine 2,3-dioxygenase 1 (Ido1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.08.020_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.celrep.2015.08.077","article-title":"Tumor-expressed Ido recruits and activates MDSCs in a Treg-dependent manner","volume":"13","author":"Holmgaard","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2020.08.020_bib46","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-12-0014","article-title":"Ido is a nodal pathogenic driver of lung cancer and metastasis development","volume":"2","author":"Smith","year":"2012","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejca.2020.08.020_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clml.2018.12.005","article-title":"A phase II study to determine the safety and efficacy of the oral inhibitor of indoleamine 2,3-dioxygenase (Ido) enzyme INCB024360 in patients with myelodysplastic syndromes","volume":"19","author":"Komrokji","year":"2019","journal-title":"Clin Lymphoma, Myeloma Leukemia"},{"issue":"1","key":"10.1016\/j.ejca.2020.08.020_bib48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1541-7786.MCR-18-0246","article-title":"Reversal of triple-negative breast cancer EMT by miR-200c decreases tryptophan catabolism and a program of immune-suppression","volume":"17","author":"Rogers","year":"2018","journal-title":"Mol Canc Res"},{"key":"10.1016\/j.ejca.2020.08.020_bib49","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1038\/onc.2008.35","article-title":"Immune escape as a fundamental trait of cancer: focus on Ido","volume":"27","author":"Prendergast","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2020.08.020_bib50","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.08.020_bib51","first-page":"e1123","article-title":"Feasibility of classification of triple negative breast cancer by immunohistochemical surrogate markers","volume":"18","author":"Kim","year":"2018","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.ejca.2020.08.020_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.10645","article-title":"Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection","volume":"101","author":"Friberg","year":"2002","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2020.08.020_bib53","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Munn","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2020.08.020_bib54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/imt.10.22","article-title":"Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation","volume":"2","author":"Muller","year":"2010","journal-title":"Immunotherapy"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920304718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920304718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:04Z","timestamp":1760732944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920304718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":54,"alternative-id":["S0959804920304718"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.08.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}